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MATIINGLY, B. A., J. K. ROWLETI, T. ELLISON AND K. RASE. Cocaine-induced behavioral sensitization: Ef-
fects of ha/operidol and SCH 23390 treatments. PHARMACOL BIOCHEM BEHAV 53(3) 481-486, !996.-The objective 
of this study was to detennine whether the development of behavioral sensitization to cocaine could be prevented by high 
doses of the dopamine receptor antagonists haloperidol and SCH 23390. In two experiments, male Wistar rats were injected 
daily for 4 days with either cocaine (15 mg/kg, IP) or vehicle in combination with haloperidol (1.0 mg/kg, IP), SCH 23390 
(0.5 mg/kg, SC), or vehicle, After the daily injections, the rats were tested for locomotor activity in photocell arenas. At 24 h 
after the last preexposure test session, all rats were given a challenge injection of cocaine (15 mg/kg, IP) and'tested for 
activity. Cocaine treatments produced a greater relative increase in locQmotor activity with repeated exposure compared to 
vehicle treatments (i.e., sensitization). Moreover, the acute activating effects of cocaine over days were blocked by both 
haloperidol and SCH 23390. The coadministration of haloperidol, but not SCH 23390, blocked the development of behavioral 
sensitization to cocaine. That is, after the cocaine challenge injection, rats pretreated with SCH 23390 and cocaine did not 
differ from rats preexposed only to cocaine, whereas rats pretreated with haloperidol and cocaine did not differ from rats 
pretreated only with vehicle. Pretreatment with haloperidol or SCH 23390 without cocaine enhanced the locomotor-activating 
effects of the subsequent cocaine challenge injection. These findings suggest that cocaine-induced behavioral sensitization 
may develop as a result of repeated dopamine 0 1- or D2-type receptor stimulation, and that brief dopamine antagonist 
treatments enhance subsequent behavioral sensitivity to cocaine. 
Dopamine antagonists D1 receptors D2 receptors 
THE REPEATED administration of both direct (e.g., apo· 
morphine) and indirect (e.g., Cocaine, amphetamine) dopa-
mine receptor agonists in rodents results in the development 
of behavioral sensitization [e.g., (14,21,30)]. This sensitization 
effect is characterized by a progressive augmentation in vari-
ous drug-induced motor behaviors and appears to be mediated 
by both pre- and postsynaptic mechanisms in mesolimbic and/ 
or nigrostriatal dopamine systems {see (11,13,28,29) for re-
views]. 
Although most dopamine agonists that induce behavioral 
sensitization result in an increased stimulation of both dopa-
mine D.- and 0 2-receptor subtypes, recent evidence suggests 
that the dopamine Di-receptor subtype plays a critical role in 
the development of behavioral sensitization. The development 
Stimulants Dopamine agonists Locomotor activity 
of behavioral sensitization to amphetamine, for example, is 
prevented by the coadministration of the selective 0 1-receptor 
antagonist SCH 23390, injected either systemically or directly 
into the ventral tegmental area (7,30,34). In contrast, coad-
ministration of D2-dopamine receptor antagonists metoclo-
pramide, pimozide, sulpiride, or R0-22-2586, does not block 
the development of behavioral sensitization to amphetamine 
(7 ,34). Likewise, the development of behavioral sensitization 
to the direct 0 1/Drdopamine receptor agonist apomorphine 
is also prevented by the coadministration of dopamine 0 1- but 
not Drreceptcir antagonists (21). Moreover, recent evidence 
indicates that the development of behavioral sensitization to 
the selective dopamine Drtype receptor agonists bromocryp-
tine and quinpirole is blocked by the coadmihistration of the 
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dopamine D,-type antagonist SCH 23390 (22,36). Thus, dopa-
mine D 1-receptor stimulation appears to be necessary for the 
induction of behavioral sensitization to both direct and indi-
rect dopamine agonists. 
Like amphetamine- and apomorphine-induced behavioral 
· sensitization, the development of behavioral sensitization to 
the locomotor-activating effects of cocaine is thought to in-
volve the stimulation of dopamine receptors [e.g., (4,10,15, 
25,32)}. Recent evidence, however, indicates that the coadmin-
istration of selective D1-type (SCH 23390) or D2-type (sulpir-
ide, YM-09151-2) antagonists does not prevent the develop-
ment .of behavioral sensitization to cocaine (16,19). These 
findings suggest the possibility that cocaine-induced behav-
ioral sensitization, unlike amphetamine-induced sensitization, 
may develop as a result of stimulation of either dopamine 
receptor subtype or through some nondopaminergic mecha-
nism. 
EXPERIMENT I 
Although low doses of the mixed D1/D2-dopamine antago-
nist haloperidol have been reported not to block the expres-
sion of cocaine-induced behavioral sensitization (18,35) or the 
development of cocaine-induced conditioned hyperactivity 
(27), 'higher doses of haloperidol have been reported to block 
the development of behavioral sensitization to cocaine in a 
2-day conditioning paradigm (9,35). 
The purpose of Experiment 1 was to determine whether the 
coadministration of a high dose of haloperidol with cocaine 
would prevent the development of behavioral sensitization in 
a repeated-treatment sensitization paradigm. 
Method 
Subjects. A total of 47 male Wistar albino rats (Harlan 
Sprague-Dawley, Indianapolis, IN), weighing between 250 
and 350 g, served as subjects. All rats were housed individually 
in hanging wire mesh cages in a colony room with a 12 L: 
12 D cycle and food and water available continuously. All 
behavioral testing was conducted during the light phase of the 
cycle. 
Apparatus. Activity measures were taken in two BRS/LVE 
cylindrical activity drums (Model 145-03; Beltsville, MD). The 
floor of each drum was 60 cm in diameter and was made of 
diamond-shaped wire mesh. The interior wall of each drum 
was 43 cm high and painted flat black. Each drum was located 
in a sound-attenuated experimental cubicle that was kept dark 
during testing. 
Two banks of three infrared photocells were mounted on 
the outside of the drum. The six photocell beams were approx-
imately 12 cm apart arranged in a criss-cross pattern 2.5 cm 
above the floor of the drum. The photocell banks were con-
nected to back-path eliminator diodes. Movement of the rat 
through a photocell beam sent a single pulse to the counters. 
Pulses spaced <0.5 s apart were recorded as a single count by 
this method. 
Drugs. Cocaine hydrochloride (Sigma, St. Louis, MO) was 
dissolved daily into distilled H,O. Haloperidol (Sigma) was 
mixed daily in a 1 OJo lactic acid solution. All injections were IP 
in a volume of 1.0 ml/kg. Control injections were given using 
the appropriate vehicle using the same route and volume as 
the corresponding drug injection. All doses were calculated 
based on the salt weight of the drug. 
Procedures. At the beginning of testing, the rats were ran-
domly assigned to one of four groups (n's = 11-12/group) 
comprising the two (vehicle or haloperidol) x two (vehicle or 
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cocaine) factorial design. On each day of the preexposure 
phase of the experiment, each rat was first injected with either 
vehicle or haloperidol (1.0 mg/kg) and then, 30 min later, 
injected with either vehicle or cocaine (15 mg/kg). Five min-
utes after this second injection, each rat was placed into the 
activity drum and activity was recorded for 20 min. This injec-
tion-test procedure was repeated daily for 4 days. Sensitization 
testing was conducted 24 h after the last preexposure test. On 
this test day, all rats were given a challenge injection of co-
caine (15 mg/kg) and then tested for activity 5 min later. 
Data analysis. Significant differences among the groups in 
mean activity counts during the preexposure sessions were 
determined with three-factor mixed analyses of variance 
(ANOV A) using haloperidol and cocaine treatments as be-
tween-group factors and daily test session as a repeated mea-
sure. The cocaine challenge test data were analyzed with a 
two-factor ANOVA. Significant interactions were evaluated 
with additional ANOV A's followed by I-tests or Neuman-
Keuls post hoc tests. 
Results 
Preexposure days 1-4. The mean activity counts of the 
four groups on the 4 preexposure days are shown in Fig. 1. 
Haloperidol produced a marked decrease in locomotor activ-
ity on each test day [haloperidol effect: F(l, 43) = 185.29, 
p < 0.0001]. Overall, cocaine produced an increase in activity 
[cocaine effect: F(l, 43) = 33.51, p < 0.0001], but this in-
crease was greater for rats pretreated with vehicle than for 
those pretreated with haloperidol [Haloperidol x Cocaine in-
teraction, F(l, 43) = 14.93, p < 0.0005]. Moreover, for rats 
pretreated with vehicle, cocaine injections produced a greater 
increase in locomotor activity compared to vehicle injections 
on preexposure day 4 than on day 1 [Cocaine x Session inter-
action: F(3, 29) = 13.26, p < 0.05; Haloperidol x Cocaine 
x Sessioninteraction:F(3, 129) = 2.84,p < 0.05]. 
Cocaine challenge test. The mean activity counts for the 
four preexposure groups following a challenge injection of co-
caine are shown in Fig. 2. The ANOVA performed on these 
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CHRONIC PRE-EXPOSURE TEST DAYS 
FIG. 1. Mean activity counts (±SEM) per 20-min session across the 
4 .preexposure days for rats injected daily with either vehicle M or 1.0 
mg/kg haloperidol (H) followed by either vehicle Or 15 mg/kg cocaine 

















ACUTE COCAINE CHALLENGE TEST 
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FIG. 2. Mean activity counts ( ± SEM) per 20-min session following a 
challenge injection of cocaine (15 mg/kg) for groups of rats previously 
treated daily with either vehicle or 1.0 mg/kg haloperidol and either 
vehicle (VEH) or 15 mg/kg cocaine (COC) for 4 days. •p < 0.05 
compared to VEHICLE-VEH group. +p < 0.06 compared to VEHI-
CLE-YEH group. 
data revealed a main effect of neither haloperidol nor cocaine 
pretreatment (p's > 0.05); however, the Haloperidol x Co-
caine pretreatment interaction was significant [F(l, 43) = 5.48, 
p < 0.03]. Subsequent analysis of this interaction indicated that 
the challenge injection of cocaine produced significantly greater 
activity in rats previously treated with vehicle and cocaine for 4 
days than for rats pretreated with only vehicle (p < 0.05). In 
contrast, the cocaine-induced activity of rats previously treated 
with haloperidol and cocaine for 4 days did not significantly 
differ from that of the vehicle-vehicle-pretreated rats (p > 
0.05). In other words, the coadministration of haloperidol with 
cocaine for 4 days blocked the development of sensitization to 
cocaine. Moreover, the challenge injection of cocaine produced 
a greater activity increase in rats previously given haloperidol 
and vehicle compared to rats previously given only vehicle injec-
tions (p < 0.06). 
EXPERIMENT 2 
The results of Experiment 1 indicate that haloperidol treat-
ments blocked the acute locomotor activating effects of co-
caine over days, as well as the development of behavioral 
sensitization. Although haloperidol has greater affinity for 
dopamine D2 than D1 receptors, the fact that selective dopa-
mine D1- or 0 2-receptor antagonists do not block behavioral 
· sensitization to cocaine (16,19) suggests that the relatively high 
dose of haloperidol used in the present study may have 
blocked sensitization to cocaine as a result of blocking both 
D1-and Drreceptor subtypes. 
Although haloperidol treatments blocked the development 
of sensitization to cocaine, repeated haloperidol treatments 
alone resulted in an enhanced locomotor response to the sub-
sequent cocaine challenge injection. In our previous study 
(19), a similar but not significant enhancement in cocaine sen-
sitivity \vas observed following repeated sulpiride or SCH 
23390 treatments. Moreover, Kurihara and Uchihashi (16) re-
ported that the coadministration of SCH 23390 or YM-
09151-2 with cocaine enhanced the activating effects of a sub-
sequent cocaine challenge injection. These investig3tors, 
however, did not include an antagonist-only control group 
during preexposure. 1 
Although we used a relatively high dose (0.3 mg/kg) of 
SCH 23390 in our previous study (19), we decided to partially 
replicate this experiment using a higher dose of SCH 23390 to 
determine: a) whether a high dose of SCH 23390, like haloper-
idol, would block the development of behavioral sensitiz3.tion 
to cocaine; and b) whether a repeated high dose of SCH 23390 
would significantly increase subsequent sensitivity to coc'a.ine. 
Experiment 2 was therefore the same as Experiment 1, except 
SCH 23390 (0.5 mg/kg), rather than haloperidol, was used. 
Method 
Subjects and procedure. Sixty male -Wistar albino rats 
(Harlan Sprague-Dawley), weighing between 250 and 350 g, 
were randomly assigned in equal numbers to one of four 
groups comprising the 2 (SCH 23390 vs. vehicle) x 2 (cocaine 
vs. vehicle) factorial design. SCH 23390 (Research Biochemi-
cals) was dissolved in distilled H,O and injected SC. The appa-
ratus and procedure was the same as in Experiment 1. 
Results 
Preexposure days 1-4. The mean activity counts of the 
four groups across the four preexposure t'est days are shown 
in Fig. 3. The 0.5-mg/kg dose of SCH ·23390 produced a 
significant decrease in locomotor activitY on each test day 
[SCH 23390 effect: F(I, 56) = 531.32, p < 0.0001]. Overall, 
cocaine produced an increase in activity [cocaine effect: F(l, 
56) = 44.30, p < 0.0001], but this increase was greater for 
rats pretreated with vehicle than for those pretreated with 
SCH 23390 [SCH 23390 x Cocaine interaction, F(l, 56) = 
28.41, p < 0.0001]. Moreover, the cocaine-induced increase 
in activity, relative to vehicle treatment, was greater for the 
vehicle pretreatment group on day 4 than on day 1 [Cocaine 
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CHRONIC PRE-EXPOSURE TIEST DAYS 
FIG. 3. Mean activity counts (±SEM) per 20-min session across the 
4 preexposure days for groups of rats injected daily with either vehi-
cle (V) or 0.5 mg/kg SCH 23390 (S) followed by Cither vehicle or 15 
mg/kg cocaine (C). •p < 0.05 compared to V-V gfoup. 
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23390 x Cocaine x Session interaction: F(3, 168) = 7.20, p 
< 0.0001]. 
Cocaine challenge test. The mean activity counts for the 
four preexposure groups following a challenge injection of 
cocaine ~re shown in Fig. 4. Although the main effect of 
cocaine did not reach significance [F(I, 56) = 3.60, p < 
0.06], the SCH 23390 x Cocaine interaction was significant 
[F(I, 56) = 6.11,p < 0.02]. Analysis of this interaction indi-
cated that groups of rats preexposed to cocaine and/or SCH 
23390 were significantly more active following a cocaine chal-
lenge injection than rats previously treated with only vehicle 
[p's < 0.05 in each case]. The activity of these three preex-
posed groups (i.e., vehicle-cocaine, SCH 23390-vehicle, and 
SCH 23390-cocaine), however, did not differ significantly fol-
lowing the cocaine challenge injection [p's > 0.05 in each 
case]. That is, rats preexposed to SCH 23390 and cocaine were 
as active follo\ving the cocaine challenge injection as the rats 
preexposed only to cocaine, and like haloperidol, preexposure 
to SCH 23390 alone resulted in an increased locomotor re-
sponse to cocaine. 
DISCUSSION 
Consistent with previous research, cocaine produced a 
greater increase in locomotor activity compared to vehicle in-
jections, with repeated treatment [e.g., (12,18,19)]. Moreover, 
the acute activating effects of cocaine over days were similarly 
attenuated by the coadministration of either haloperidol or 
SCH 23390. This finding is also consistent with previous re-
search [e.g., (3,7,21)], which suggests that the expression of 
various dopamine agonist-induced behavioral effects requires 
the concomitant stimulation of both dopamine D1 and D2 re-
ceptors. 
Although both dopamine antagonists blocked the acute lo-
comotor-activating effects of cocaine, only haloperidol pre-
vented the development of behavioral sensitization. This find-



















CHRONIC PRE-EXPOSURE CONDITION 
FIG. 4. Mean activity counts (±SEM) per 20-min session following 
a challenge injection of cocaine for groups of rats previously treated 
daily for 4 days with vehicle or 0.5 mg/kg SCH 23390· and either 
vehicle (VEH) or 15 mg/kg cocaine (COC). •p < 0.05 compared to 
VEHICLE-VEH group. 
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coadministration of a relatively high dose of haloperidol (0.5 
mg/kg) blocks the development of sensitization to a single 
high dose (40 mg/kg) of cocaine (35). Similarly, haloperidol 
also blocks the development of sensitization to repeated apo-
morphine treatments (20). As· noted previously, the coadmin-
istration of more selective dopamine Drtype antagonists does 
not prevent the development of sensitization to cocaine (16, 
19), amphetamine (7,30,34), or apomorphine (21). Likewise, 
selective dopamine D1-type antagonists are ineffective in 
blocking cocaine-induced behavioral sensitization (Experi-
ment 2) (16,19). Taken together, these findings suggest that 
the prevention of cocaine-induced behavioral sensitization 
may require the blockade of both dopamine D,- and D2-type 
receptors. 
It should be noted, however, that the neurochemical effects 
of cocaine and haloperidol are not limited to dopamine sys-
tems. Cocaine, for example, blocks neuronal reuptake of sero-
tonin and norepinepbrine as well as dopamine (8). Moreover, 
the acute locomotor-activating effects of cocaine are blocked 
by adrenergic, serotonergic, and a-receptor antagonists (2,31, 
37), and repeated cocaine treatments produce alterations in 
other neurochemical systems besides dopamine (6,17,33). 
Likewise, in addition to dopamine receptors, haloperidol has 
been reported to bind to both serotonin and sigma sites 
(23,26). Thus, it is possible that the ability of high doses of 
haloperidol to block the development of cocaine-induced be-
havioral sensitization may be related to its nondopaminergic 
effects or to some combination of dopaminergic and nondo-
paminergic effects. 
Also, it might be argued that the effectiveness of haloperi-
dol in blocking the development of behavioral sensitization to 
cocaine, compared to other dopamine antagonists, may be 
related to its rather long ·half-life. In rats, the brain tissue 
half-life of haloperidol has been reported to be approximately 
5 h (5). Because the cocaine challenge test was conducted only 
24 h following the last the haloperidol treatment, a small 
amount of haloperidol may have been present, thereby reduc-
ing the locomotor-activating effects of cocaine. If this latter 
explanation were· correct, however, the cocaine-induced activ-
ity increase observed in rats previously treated with haloperi-
dol and vehicle for 4 days would also have been significantly 
reduced. As noted previously, the cocaine-induced activity of 
these haloperidol-treated rats did not differ significantly from 
that of rats previously treated with only cocaine (cf., Fig. 2). 
Thus, drug accumulation would not appear to account for the 
effectiveness of haloperidol in preventing the development of 
behavioral sensitization to cocaine. 
Another intriguing, yet complicating, finding of the pres-
ent study is that brief treatments (i.e., 4 days) with relatively 
high doses of either haloperidol or SCH 23390 enhanced the 
locomotor-activating effects of a subsequent cocaine challenge 
injection. As noted earlier, we observed a similar tendency 
after seven daily injections of sulpiride (100 mg/kg) or a lower 
dose of SCH 23390 (0.30 mg/kg) in a previous study with rats 
(19); and Kurihara and Uchihashi (16) reported that coadmin-
istration of SCH 23390 or YM-09151-2 with cocaine increases 
subsequent sensitivity to cocaine in mice. Consistent with 
these antagonist-induced changes in cocaine sensitivity, it has 
recently been reported that four daily treatments with the se-
lective dopamine D,-type agonist A-77636 decreases subse-
quent sensitivity to the locomotor-activating effects of cocaine 
(1). Moreover, repeated treatment (5 days) with the mixed 
dopamine antagonist cis-(Z)-flupentixol has recently been re-
ported to increase subsequent sensitivity to cocaine in a self-
administration paradigm (24). Thus, brief antagonist treat-
J 
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ments appear to enhance sensitivity to both the locomotor and 
rewarding effects of cocaine. 
Although this antagonist-induced increase in cocaine sensi-
tivity is interesting, it complicates the interpretation of the 
sensitization results. For example, in Experiment 2, rats preex-
posed to SCH 23390 and cocaine did not differ in activity 
from those pretreated only with cocaine on the cocaine chal-
lenge test. This suggests that SCH 23390 did not block the 
development of sensitization to cocaine. However. the SCH 
23390-cocaine-pretreated rats also did not differ in activity 
from rats previously treated with only SCH 23390 on this 
cocaine challenge test. Because cocaine pretreatment did not 
add to the effect of SCH 23390 pretreatment, it might be 
argued that SCH 23390 did block cocaine-induced sensitiza-
tion. Thus, it is possible that any attenuation of sensitization 
to cocaine resulting from the coadministration of selective 
antagonists might be masked by the antagonist-induced in-
crease in cocaine sensitivity. Clearly, additional information 
concerning the mechanisms mediating this brief antagonist-
induced increase in cocaine sensitivity is needed before an 
unambiguous interpretation is possible. Although haloperidol 
pretreatments also increased subsequent sensitivity to cocaine, 
rats pretreated with haloperidol and cocaine did not differ 
after the cocaine challenge injection from rats pretreated with 
only vehicle for 4 days. Thus, haloperidol clearly blocked the 
development of sensitization. 
In conclusion, the present results indicate that brief pre-
treatments with either haloperidol or SCH 23390 increase sub-
sequent sensitivity to cocaine. Further, the results indicate that 
high doses of haloperidol, but not SCH 23390, block the de-
velopment of behavioral sensitization to cocaine. These find-
ings, together with previous research, sukgest that cocalne-
induced behavioral sensitization may be' mediated by the 
repeated stimulation of either dopamine; receptor subtype 
alone. Moreover, because sensitization to!amphetamine and 
apomorphine, but not cocaine, is prevented by selective dopa-
mine D1-type antagonists [e.g., (7,19,21,34)], these results sug-
gest that the development of sensitization to these three dopa-
mine agonists may be mediated by different neurochemical 
mechanisms. 
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